Related Experiment Video

Updated: Mar 2, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.3K

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

Tarra Evans1, Ursula Matulonis2

  • 1Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA.

Therapeutic Advances in Medical Oncology
|May 12, 2017
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise in ovarian cancer treatment, particularly for BRCA-mutated cancers. Combinations with antiangiogenic agents are well-tolerated and effective in both BRCA-mutated and wild-type ovarian cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase (PARP) inhibitors represent a significant advancement in ovarian cancer therapy.
  • Their efficacy is linked to DNA repair vulnerabilities in cancer cells, especially those with BRCA mutations.

Purpose of the Study:

  • To review the mechanisms of action and clinical applications of PARP inhibitors in ovarian cancer.
  • To evaluate the efficacy and tolerability of PARP inhibitors as single agents and in combination therapies.

Main Methods:

  • Review of clinical trial data and scientific literature on PARP inhibitors in ovarian cancer.
  • Analysis of efficacy in BRCA-mutated and BRCA wild-type ovarian cancers.
  • Assessment of combination therapies, including chemotherapy and antiangiogenic agents.

Main Results:

  • PARP inhibitors are most effective as single agents in BRCA-mutated ovarian cancers.
  • Single-agent activity extends to BRCA wild-type cancers with specific clinical features (e.g., platinum sensitivity).
  • Combinations with antiangiogenic agents show promising tolerability and efficacy in both BRCA-mutated and wild-type settings, unlike chemotherapy combinations.

Conclusions:

  • PARP inhibitors are a vital therapeutic option for ovarian cancer, with expanding applications beyond BRCA mutations.
  • Combination therapy with antiangiogenic agents offers a promising and well-tolerated strategy for ovarian cancer treatment.
  • Ongoing clinical trials continue to explore the full potential of PARP inhibitor combinations.
Keywords:
BRCA mutationsPARP inhibitorsovarian cancertargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K